Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-124559
Filing Date
2024-11-12
Accepted
2024-11-12 07:15:24
Documents
77
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q apge-20240930.htm   iXBRL 10-Q 2301564
2 EX-31.1 apge-ex31_1.htm EX-31.1 15229
3 EX-31.2 apge-ex31_2.htm EX-31.2 15256
4 EX-32.1 apge-ex32_1.htm EX-32.1 12536
  Complete submission text file 0000950170-24-124559.txt   8830270

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT apge-20240930.xsd EX-101.SCH 1182555
80 EXTRACTED XBRL INSTANCE DOCUMENT apge-20240930_htm.xml XML 1440039
Mailing Address 221 CRESCENT ST. BUILDING 17, SUITE 102B WALTHAM MA 02453
Business Address 221 CRESCENT ST. BUILDING 17, SUITE 102B WALTHAM MA 02453 650-394-5230
Apogee Therapeutics, Inc. (Filer) CIK: 0001974640 (see all company filings)

EIN.: 934958665 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41740 | Film No.: 241443248
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)